Plain-English translation of NCT07297329 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether adding to the standard three-drug combination used to treat multiple myeloma works better and is safe. You would receive either the standard three-drug treatment alone, or the same three drugs plus this new medication. The trial will measure how well the treatment works and what side effects occur.
Multiple myeloma is a serious blood cancer, and while current treatments help many patients, researchers want to see if adding this new medication can improve outcomes and help more people live longer without their cancer getting worse.
You likely qualify if…
You likely don't qualify if…
You will first go through a screening period of up to 28 days where doctors confirm you qualify. Then you will be randomly assigned to receive either the standard three-drug combination or that same combination plus the new medication. You will receive treatment in 28-day cycles and continue until your cancer stops responding or side effects become too difficult. Throughout the trial, you'll have regular blood tests, physical exams, heart tracings, and imaging scans to monitor how you're doing.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China